CO5570682A2 - Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores - Google Patents

Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores

Info

Publication number
CO5570682A2
CO5570682A2 CO04035672A CO04035672A CO5570682A2 CO 5570682 A2 CO5570682 A2 CO 5570682A2 CO 04035672 A CO04035672 A CO 04035672A CO 04035672 A CO04035672 A CO 04035672A CO 5570682 A2 CO5570682 A2 CO 5570682A2
Authority
CO
Colombia
Prior art keywords
isomer
isomeric mixture
compound
blends
immunomodulating agents
Prior art date
Application number
CO04035672A
Other languages
English (en)
Spanish (es)
Inventor
Naicker Selvaraj
Randall W Yatscoff
Robert T Foster
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of CO5570682A2 publication Critical patent/CO5570682A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CO04035672A 2001-10-19 2004-04-19 Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores CO5570682A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19

Publications (1)

Publication Number Publication Date
CO5570682A2 true CO5570682A2 (es) 2005-10-31

Family

ID=23358378

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04035672A CO5570682A2 (es) 2001-10-19 2004-04-19 Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores

Country Status (37)

Country Link
US (2) US20110092669A1 (en:Method)
EP (2) EP1816138A1 (en:Method)
JP (4) JP2005511538A (en:Method)
KR (1) KR100992850B1 (en:Method)
CN (1) CN100344648C (en:Method)
AR (1) AR036853A1 (en:Method)
AT (1) ATE401339T1 (en:Method)
AU (1) AU2002331510B2 (en:Method)
BE (1) BE2022C547I2 (en:Method)
BR (1) BR0213659A (en:Method)
CA (2) CA2460685C (en:Method)
CO (1) CO5570682A2 (en:Method)
CY (2) CY1108410T1 (en:Method)
DE (1) DE60227686D1 (en:Method)
DK (1) DK1436322T3 (en:Method)
EC (3) ECSP045060A (en:Method)
ES (1) ES2310604T3 (en:Method)
FI (1) FIC20220041I1 (en:Method)
FR (1) FR22C1051I2 (en:Method)
HR (1) HRP20040353B1 (en:Method)
IL (2) IL160762A0 (en:Method)
LT (1) LTC1436322I2 (en:Method)
MA (1) MA26337A1 (en:Method)
ME (1) ME00487B (en:Method)
MX (1) MXPA04003624A (en:Method)
MY (1) MY187182A (en:Method)
NL (1) NL301200I2 (en:Method)
NO (2) NO331745B1 (en:Method)
NZ (1) NZ531945A (en:Method)
PL (1) PL210697B1 (en:Method)
PT (1) PT1436322E (en:Method)
RU (1) RU2337106C2 (en:Method)
SI (1) SI1436322T1 (en:Method)
TN (1) TNSN04069A1 (en:Method)
UY (1) UY27502A1 (en:Method)
WO (1) WO2003033527A2 (en:Method)
ZA (1) ZA200402270B (en:Method)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100334106C (zh) 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
MX2007007262A (es) * 2004-12-17 2007-10-19 Isotechnika Inc Metabolitos de analogos de ciclosporina.
US7872097B2 (en) * 2005-10-26 2011-01-18 Astellas Pharma Inc. Cyclic peptide compounds
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008139986A1 (en) * 2007-05-02 2008-11-20 Astellas Pharma Inc., New cyclic peptide compounds
CN101918019B (zh) 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
JP2012529509A (ja) 2009-06-09 2012-11-22 ラックス・バイオサイエンシーズ・インコーポレイテッド 眼科用用途のための局所薬物送達システム
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
JP2020510249A (ja) * 2016-11-30 2020-04-02 シュレーディンガー インコーポレイテッドSchrodinger,Inc. 化学の遷移状態を計算するためのグラフィカルユーザインタフェース
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
IL296586A (en) * 2020-03-26 2022-11-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and uses thereof
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
EP4584279A1 (en) * 2022-09-09 2025-07-16 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
IT202300001056A1 (it) * 2023-01-25 2024-07-25 Procos Spa Nuovo processo per la preparazione di voclosporina amorfa
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
WO2025141456A1 (en) * 2023-12-27 2025-07-03 Indena S.P.A. Process for the preparation of voclosporin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278545A (en) * 1979-09-12 1981-07-14 The Bendix Corporation Apparatus for separating solids and liquid components
CH670644A5 (en:Method) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
DE3884470T2 (de) * 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
CZ291641B6 (cs) * 1996-06-19 2003-04-16 Novartis Ag Přípravek obsahující cyklosporin
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
NZ502362A (en) * 1997-10-08 2001-05-25 Isotechnika Inc Deuterated cyclosporine A derivatives and their use as immunomodulating agents
CN100334106C (zh) * 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Also Published As

Publication number Publication date
ZA200402270B (en) 2005-05-25
PL210697B1 (pl) 2012-02-29
ME00487B (me) 2011-10-10
NL301200I2 (nl) 2024-07-25
CY2022030I1 (el) 2023-01-27
CY1108410T1 (el) 2012-05-23
IL160762A0 (en) 2004-08-31
ECSP045059A (es) 2004-07-23
NO20042029L (no) 2004-05-14
SI1436322T1 (sl) 2008-12-31
JP5272140B2 (ja) 2013-08-28
CN1571794A (zh) 2005-01-26
KR100992850B1 (ko) 2010-11-09
RU2004110941A (ru) 2005-08-10
NO331745B1 (no) 2012-03-19
JP2005511538A (ja) 2005-04-28
CA2727642C (en) 2014-02-04
FR22C1051I1 (fr) 2022-12-16
MY187182A (en) 2021-09-08
BR0213659A (pt) 2004-10-26
US20110092669A1 (en) 2011-04-21
JP2009197036A (ja) 2009-09-03
ECSP045060A (es) 2004-07-23
NO2022042I1 (no) 2022-10-14
RU2337106C2 (ru) 2008-10-27
CA2460685C (en) 2014-05-27
DK1436322T3 (da) 2008-11-03
IL160762A (en) 2010-11-30
HK1062567A1 (en) 2004-11-12
WO2003033527A3 (en) 2003-10-16
FR22C1051I2 (fr) 2023-11-17
CA2460685A1 (en) 2003-04-24
CN100344648C (zh) 2007-10-24
MA26337A1 (fr) 2004-10-01
ATE401339T1 (de) 2008-08-15
TNSN04069A1 (en) 2006-06-01
KR20050037421A (ko) 2005-04-21
PL370501A1 (en) 2005-05-30
MXPA04003624A (es) 2004-12-06
DE60227686D1 (de) 2008-08-28
EP1816138A1 (en) 2007-08-08
WO2003033527A2 (en) 2003-04-24
EP1436322B1 (en) 2008-07-16
PT1436322E (pt) 2008-10-23
US20140288266A1 (en) 2014-09-25
NZ531945A (en) 2006-01-27
CA2727642A1 (en) 2003-04-24
AU2002331510B2 (en) 2008-05-01
AR036853A1 (es) 2004-10-06
EP1436322A2 (en) 2004-07-14
HRP20040353A2 (en) 2005-04-30
UY27502A1 (es) 2003-04-30
JP2013136597A (ja) 2013-07-11
ECSP045061A (es) 2004-08-27
ES2310604T3 (es) 2009-01-16
HRP20040353B1 (hr) 2012-10-31
BE2022C547I2 (en:Method) 2022-10-19
FIC20220041I1 (fi) 2022-10-14
LTC1436322I2 (en:Method) 2023-06-26
CY2022030I2 (el) 2023-06-09
LTPA2022521I1 (en:Method) 2022-11-10
JP2011006417A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
CO5570682A2 (es) Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
GT200200114A (es) Champues con alcohol de behenilo
BR0116170A (pt) Composição de limpeza e sanitização efetiva para remoção de espuma de sabão
PA8557401A1 (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
AR067364A1 (es) Formulaciones solidas de artropodicidas de carboxamida
BRPI0805072B8 (pt) Composições organizadas compreendendo betaína
PA8493401A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
AR020999A1 (es) Composiciones y proceso para la elaboracion de isotretinoina
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
UY27446A1 (es) Nuevos compuestos
DOP2007000028A (es) Composiciones de ramnolípidos y métodos relacionados con su uso
ECSP088106A (es) Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina
BRPI0606860A2 (pt) composições detergentes
UY27894A1 (es) Derivados de cinamida.
GB2440843A (en) Liquid sealant and methods of use
AR046123A1 (es) Aislamiento de celulas simil-celulas madre, uso de las mismas
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
ES2194083T3 (es) Utilizacion en una composicion como activador y/o estabilizador de ciclooxigenasa de al menos un derivado de pirimidina sustituido en 6.
AR001932A1 (es) Un hidrosol de una sal de un complejo procedimiento para su obtención una dispersion de éster polivínilico un procedimiento para su obtención y el usode mismo
AR051217A1 (es) Mezclas isomericas de esteres de dinitro-octilfenilo y mezclas fungicidas sinergicas de los mismos
PA8623101A1 (es) Compuestos farmaceuticamente activos
GT200600173A (es) Forma purificada de tranaproget
WO2007033288A3 (en) Composite paste for dental prostheses

Legal Events

Date Code Title Description
FC Application refused